WO2017209721A1 - Médicament dérivé d'enzymes présentes dans la salive humaine destiné à la prévention de la formation d'une taie ou de la cataracte - Google Patents

Médicament dérivé d'enzymes présentes dans la salive humaine destiné à la prévention de la formation d'une taie ou de la cataracte Download PDF

Info

Publication number
WO2017209721A1
WO2017209721A1 PCT/TR2017/050243 TR2017050243W WO2017209721A1 WO 2017209721 A1 WO2017209721 A1 WO 2017209721A1 TR 2017050243 W TR2017050243 W TR 2017050243W WO 2017209721 A1 WO2017209721 A1 WO 2017209721A1
Authority
WO
WIPO (PCT)
Prior art keywords
human saliva
drug
cataract
corneal clouding
enzymes present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2017/050243
Other languages
English (en)
Inventor
Eda ALEMDAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2017209721A1 publication Critical patent/WO2017209721A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)

Definitions

  • This invention is related to a drug embodied to prevent corneal clouding or cataract diseases.
  • the invention is related to a drug that is derived from various enzymes present in the human saliva and that is embodied to prevent formation of corneal clouding and cataract diseases.
  • Cataract disease is the loss of transparency and clouding of the natural eye lens that is positioned behind the pupil and that enables vision. In other words, it is the distortion of vision as if looking behind a foggy glass.
  • the natural lens membrane where the artificial lens is positioned may opacify in time and the patient may start seeing blurry and cloudy as it was before the cataract surgery.
  • RNAs and 400 types of beneficial bacteria that have constructive effects.
  • components in the saliva such as the growth factors in the saliva that are effective in cell growth and renewal and lysozyme enzyme that is responsible of digesting cell wall and prevention of bacterial infections.
  • the saliva mixed with Potassium Rhodanide salt and molecule groups exposed to some conversions by the help of Lactoperoxidase exhibits antibacterial properties.
  • the ⁇ -glucuronidase enzyme that catalyzes complex carbohydrates and that is present in the Lysozyme is in the content of the fluid.
  • an ophthalmic mixture that comprises of Lysozyme reformed after being extracted from a healthy individual, one or more lacrophyl substances, water and one or more preferably therapeutic substances is mentioned. Said mixture is helpful in eye dryness (xerophthalmia), treatment of eye injuries and cleaning of contact lenses.
  • the object of this invention is to embody a drug derived by using human saliva and various enzymes within to be used in treatment of cataract disease.
  • the drug that is embodied to achieve the objects of the invention will, in its basic form, comprise Beta-glucuronidase, Lysozyme and Lactoperoxidase enzymes, which are present in the human saliva.
  • the enzymes present in the human saliva are extracted and turned into a drug that can be used in treatment of cataract and corneal clouding.
  • the drug will preferably be administered to the eye as an eye drop.
  • Beta- glucuronidase will be used.
  • the eyepiece (lens) that lost its transparency has been removed by surgical operation, it is immersed into saliva extracted from a healthy patient and it is examined under microscope if transparency has been eventually recovered for the clouded eye.
  • the Beta-glucuronidase enzyme is concentrated, it is observed that after 48 hours of treatment the colour of the eyepiece has gained transparency. Then a chemical component has been prepared from saliva in laboratory environment and turned into a medical drop.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un médicament qui est dérivé de diverses enzymes présentes dans la salive humaine et qui est conçu pour prévenir la formation de maladies de type taie et cataracte. Le médicament qui est conçu pour atteindre les objectifs de l'invention comprendra, dans sa forme basique, des enzymes bêta-glucuronidase, lysozyme et lactoperoxydase qui sont présentes dans la salive humaine.
PCT/TR2017/050243 2016-06-02 2017-06-02 Médicament dérivé d'enzymes présentes dans la salive humaine destiné à la prévention de la formation d'une taie ou de la cataracte Ceased WO2017209721A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2016/07449 2016-06-02
TR201607449 2016-06-02

Publications (1)

Publication Number Publication Date
WO2017209721A1 true WO2017209721A1 (fr) 2017-12-07

Family

ID=59930741

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2017/050243 Ceased WO2017209721A1 (fr) 2016-06-02 2017-06-02 Médicament dérivé d'enzymes présentes dans la salive humaine destiné à la prévention de la formation d'une taie ou de la cataracte

Country Status (1)

Country Link
WO (1) WO2017209721A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4961927A (en) 1986-12-19 1990-10-09 Eisai Co., Ltd. Clear solution containing lysozyme hydrochloride and dipotassium glycyrrhizinate
JPH10158160A (ja) 1996-11-29 1998-06-16 Santen Pharmaceut Co Ltd 遅延型アレルギー抑制剤
US20030124112A1 (en) 2000-05-04 2003-07-03 Ilona Molnarne-Kahan Use of a lacrophyl preparation in eye drops containing therpeutically active compounds
WO2006019844A1 (fr) 2004-07-15 2006-02-23 Nanobac Life Sciences Procedes et compositions pour le traitement de maladies caracterisees par une calcification pathologique
US20080213188A1 (en) 2007-03-02 2008-09-04 Saint Simeon Lda Novel ophthalmic compositions containing human recombinant lysozyme and use thereof for treating eye conditions and as contact lens solutions
WO2012093753A1 (fr) * 2011-01-05 2012-07-12 Snu R&Db Foundation Salive artificielle comportant de l'acide hyaluronique
US20140377246A1 (en) * 2013-06-19 2014-12-25 Carol Ann Foundation and International Morquio Organization Enzyme replacement therapy for treating mps vii related bone lesions using a chemically modified enzyme

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4961927A (en) 1986-12-19 1990-10-09 Eisai Co., Ltd. Clear solution containing lysozyme hydrochloride and dipotassium glycyrrhizinate
JPH10158160A (ja) 1996-11-29 1998-06-16 Santen Pharmaceut Co Ltd 遅延型アレルギー抑制剤
US20030124112A1 (en) 2000-05-04 2003-07-03 Ilona Molnarne-Kahan Use of a lacrophyl preparation in eye drops containing therpeutically active compounds
WO2006019844A1 (fr) 2004-07-15 2006-02-23 Nanobac Life Sciences Procedes et compositions pour le traitement de maladies caracterisees par une calcification pathologique
US20080213188A1 (en) 2007-03-02 2008-09-04 Saint Simeon Lda Novel ophthalmic compositions containing human recombinant lysozyme and use thereof for treating eye conditions and as contact lens solutions
WO2012093753A1 (fr) * 2011-01-05 2012-07-12 Snu R&Db Foundation Salive artificielle comportant de l'acide hyaluronique
US20140377246A1 (en) * 2013-06-19 2014-12-25 Carol Ann Foundation and International Morquio Organization Enzyme replacement therapy for treating mps vii related bone lesions using a chemically modified enzyme

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SERRATRICE NICOLAS ET AL: "Corrective GUSB transfer to the canine mucopolysaccharidosis VII cornea using a helper-dependent canine adenovirus vector", JOURNAL OF CONTROLLED RELEASE, vol. 181, 4 March 2014 (2014-03-04), pages 22 - 31, XP028844214, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2014.02.022 *

Similar Documents

Publication Publication Date Title
Huang et al. Preparation of acellular scaffold for corneal tissue engineering by supercritical carbon dioxide extraction technology
Bleyen et al. Spontaneous corneal clearing after Descemet's stripping
Soh et al. Predicative factors for corneal endothelial cell migration
US20170334969A1 (en) Method for producing high-concentration collagen for using as medical material
CA2140834A1 (fr) Methode d'elimination des prions des collagenes et collagenes ainsi obtenus
RU2642964C2 (ru) Хондроитин для применения в медицине
Patchan et al. Evaluation of the biocompatibility of regenerated cellulose hydrogels with high strength and transparency for ocular applications
CN102225220A (zh) 眼科手术粘弹剂
US20160303288A1 (en) Method for preparing biocompatible cornea and decellularization composition for biocompatible tissue
Mansour et al. The effect of source animal age, decellularization protocol, and sterilization method on bovine acellular dermal matrix as a scaffold for wound healing and skin regeneration
Sharifi et al. Critical media attributes in E-beam sterilization of corneal tissue
Čanović et al. Intraocular lens (IOL) materials
WO2017209721A1 (fr) Médicament dérivé d'enzymes présentes dans la salive humaine destiné à la prévention de la formation d'une taie ou de la cataracte
CN104474535A (zh) 一种治疗糖尿病足的水溶性凝胶
WO2017207845A1 (fr) Procédé pour évaluer la cytotoxicité de substances chimiques
DE112016003921T5 (de) Endotoxin-reduziertes Thermolysin
US20250161371A1 (en) Regenerative helminth containing compositions and uses thereof
Jorge E et al. In Vivo Biocompatibility of Chitosan and Collagen–vitrigel Membranes for Corneal Scaffolding: A Comparative Analysis
KR102517172B1 (ko) 컬러 콘택트렌즈용 코팅액 및 이를 포함하여 제조된 컬러 콘택트렌즈
US9309304B2 (en) Glycation cross-link breakers to increase resistance to enzymatic degradation
RU2234310C1 (ru) Способ приготовления вискоэластичного протектора эндотелия роговицы
Mensah Generation of a drug-incorporated membrane for biomedical applications
Marín-Payá et al. Use of Vivostat PRF® in Acanthamoeba keratitis
JP6206782B2 (ja) 人工涙液の組成物
Matsuo Cyclic tetrasaccharide delays cataract formation in the lens in vitro

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17771897

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17771897

Country of ref document: EP

Kind code of ref document: A1